Literature DB >> 24528892

Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.

S T Lindstrom1, E K C Wong.   

Abstract

BACKGROUND AND AIM: Community-acquired pneumonia (CAP) is a leading cause of mortality, morbidity and hospital admission, which places strain on our healthcare system. Procalcitonin (PCT) is a biomarker of bacterial infection which may help gauge the severity and prognosis of patients with CAP. In addition to clinical predictors, PCT may assist in decisions pertaining to timing of discharge from hospital and the discontinuation of antibiotics. This study aimed to determine the predictive role of PCT measurement in reducing hospital admissions, length of stay (LOS) and antibiotic (AB) usage in patients with CAP.
METHODS: A prospective, single-blinded, externally controlled study of consenting adult patients admitted with CAP. PCT levels were obtained on day 1 and day 3 (when indicated). Investigator-evaluated clinical parameters, together with results of PCT levels, determined the timing of oral AB switch and discharge from hospital. This process was compared against standard practice, but was not actually implemented, for the purpose of this study.
RESULTS: Sixty patients were included in the study. The mean age was 66.5 ± 21.2 years (56.3% male). The average Pneumonia Severity Index was 93 ± 39 (class IV) and the median CURB-65 was 2. The mean LOS for the standard practice cohort was 5.3 ± 4.6 days versus calculated LOS using the PCT guidance pathway of 3.7 ± 2.8 days. (P = 0.00006).
CONCLUSIONS: Our study supports the hypothesis that by incorporation of PCT levels, hospital admission and LOS in patients with CAP can be reduced. A randomised prospective clinical trial is planned in an attempt to help confirm these findings.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  CURB-65; PSI; antibiotics; community-acquired pneumonia; length of stay; procalcitonin

Mesh:

Substances:

Year:  2014        PMID: 24528892     DOI: 10.1111/imj.12374

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  4 in total

1.  Admission lysophosphatidylethanolamine acyltransferase level predicts the severity and prognosis of community-acquired pneumonia.

Authors:  Li Chen; Lili Zhao; Ying Shang; Yu Xu; Zhancheng Gao
Journal:  Infection       Date:  2021-03-10       Impact factor: 3.553

2.  Effect of Vitamin D Supplementation on Procalcitonin as Prognostic Biomarker in Patients with Ventilator Associated Pneumonia Complicated with Vitamin D Deficiency.

Authors:  Amir Ebrahim Miroliaee; Jamshid Salamzadeh; Shervin Shokouhi; Alireza Fatemi; Seyed Hossein Ardehali; Mohammad Reza Hajiesmaeili; Zahra Sahraei
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

3.  Biomarker-based diagnosis of pacemaker and implantable cardioverter defibrillator pocket infections: A prospective, multicentre, case-control evaluation.

Authors:  Carsten Lennerz; Hrvoje Vrazic; Bernhard Haller; Siegmund Braun; Tobias Petzold; Ilka Ott; Agnes Lennerz; Jonathan Michel; Patrick Blažek; Isabel Deisenhofer; Peter Whittaker; Christof Kolb
Journal:  PLoS One       Date:  2017-03-06       Impact factor: 3.240

4.  Association of serum procalcitonin and C-reactive protein levels with CURB-65 criteria among patients with community-acquired pneumonia.

Authors:  Fariba Keramat; Hamid Reza Ghasemi Basir; Elham Abdoli; Arghavan Shafiei Aghdam; Jalal Poorolajal
Journal:  Int J Gen Med       Date:  2018-06-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.